Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-08-21
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines, shares in CASGEVY economics with Vertex, and is advancing broader in vivo, cell therapy, and cardiometabolic programs.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved Beachhead, Platform Still on Trial
One approved therapy and a real cash base give this story substance, but the rerating still depends on proving a broader cardiovascular and cell-therapy franchise. The upside is meaningful if even one owned asset becomes commercially credible by 2031.

Analysis

Thesis
CRISPR Therapeutics has already cleared the hardest trust gate with the first approved CRISPR therapy; if CASGEVY converts into steadier economics and one owned cardiometabolic or cell-therapy asset becomes commercially credible, the stock can rerate from cash-backed science optionality into a multi-franchise gene-medicine platform by 2031.
Last Economy Alignment
AI makes design and development cheaper, but CRISPR captures value in IP, regulated trust, manufacturing know-how, and long-term evidence. The main drag is that Vertex controls much of the flagship commercial surface and biology still scales slower than software.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
The upside case does not require every program to work. A steadier approved-product economic stream plus one owned franchise becoming real would change how investors value the business: less as cash plus experiments, more as a repeatable genetic-medicines company. That can support a meaningful rerating, but partner dependence, regulatory friction, and remaining proof gates keep the case in fast-growth rather than true hypergrowth territory.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
This is a proof-conversion story more than a funding story. The balance sheet buys time, but value still hinges on turning one approved therapy into cleaner economics and proving that at least one owned program can clear safety, durability, reimbursement, and manufacturing filters.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.53
They own valuable gene-editing know-how, regulatory trust, and some manufacturing, so AI helps them design drugs faster without replacing the hard part of getting therapies safely into patients. The risk is that biology, reimbursement, and treatment-center bottlenecks still matter more than software speed, and Vertex controls much of the first product's commercial surface.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$87.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case